CORONA REMEDIES
Back to Cashflow Statement
|
CORONA REMEDIES Last 5 Year Net Cash Inflow / Outflow History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Net Cash Inflow / Outflow | ₹-1.39 Cr | ₹0.06 Cr | ₹-11 Cr | ₹7.71 Cr |
What is the latest Net Cash Inflow / Outflow ratio of CORONA REMEDIES ?
| Year | Net Cash Inflow / Outflow |
|---|---|
| Mar2026 | ₹-1.39 Cr |
| Mar2025 | ₹0.06 Cr |
| Mar2024 | ₹-11 Cr |
| Mar2023 | ₹7.71 Cr |
How is Net Cash Inflow / Outflow of CORONA REMEDIES Trending?
| Years | Net Cash Inflow / Outflow | % Change | |
|---|---|---|---|
| Mar2026 | ₹-1.39 Cr | Negative | |
| Mar2025 | ₹0.06 Cr | Positive | |
| Mar2024 | ₹-11 Cr | Negative | |
| Mar2023 | ₹7.71 Cr | - | |
Compare Net Cash Inflow / Outflow of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹11,566.5 Cr | 1.4% | 11.3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹446,792.0 Cr | 1.4% | 1.2% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,152.0 Cr | -0.5% | -0.6% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹152,915.0 Cr | 2.1% | 1.5% | 42.2% | Stock Analytics | |
| CIPLA | ₹116,354.0 Cr | 6.4% | 1.6% | -3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,681.0 Cr | 6.2% | 1.6% | 0.2% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 1.4% |
11.3% |
|
| SENSEX | -0.4% |
0.8% |
-5.3% |
You may also like the below Video Courses